Latent mycobacterium tuberculosis infection: Reply

New England Journal of Medicine

Volumn 373, Issue 12, 2015, Pages 1179-1180

  Getahun, Haileyesus ^a   Chaisson, Richard E ^b   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUBERCULIN TEST; MYCOBACTERIUM TUBERCULOSIS;

ISONIAZID; TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84941747097     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1508223     Document Type: Letter

References (5)

1. King TC, Upfal M, Gottlieb A, et al. T-SPOT.TB interferongamma release assay performance in healthcare worker screening at nineteen U.S. hospitals. Am J Respir Crit Care Med 2015; 192:367-73.
2. Dorman SE, Belknap R, Graviss EA, et al. Interferon-? release assays and tuberculin skin testing for diagnosis of laten t tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014;189:77-87.
3. Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baselin e results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis 2015;15:310-9.
4. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: wh at is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204.
5. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011;8(3):e1001012.